Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...
Morgan Stanley closed $12.79 short of its 52-week high ($136.24), which the company achieved on November 25th.
While Citi, BofA and Goldman touted their biggest cohorts of managing directors in years, Morgan Stanley elevated greater ...
Mike Wilson, Morgan Stanley's chief investment officer, has some advice for anyone looking to advance in their career: Take ...
The popularity of alcohol-free Guinness won’t protect the shares of its owner Diageo Plc from the growing trend toward health ...
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to ...
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate ...
Among 26 home price forecast models tracked by ResiClub, Morgan Stanley is the most bearish on the 2025 housing market.
Robert Chen and his team like strategies like direct indexing because they systematically tax loss harvest throughout the ...